{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T01:03:45Z","timestamp":1772931825043,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T00:00:00Z","timestamp":1481068800000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.vaccine.2015.10.023","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T23:35:39Z","timestamp":1445902539000},"page":"7344-7351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development"],"prefix":"10.1016","volume":"33","author":[{"given":"Cheng","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingshu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Youl","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing-Pui","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason G.D.","family":"Gall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Colloca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Seder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Nabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.10.023_bib0210","series-title":"Virus taxonomy: classification and nomenclature of viruses. Ninth Report of the International Committee on Taxonomy of Viruses","first-page":"95","article-title":"Family Adenoviridae","author":"Harrach","year":"2011"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0215","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.1016\/j.vaccine.2010.09.079","article-title":"Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans","volume":"28","author":"Bett","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0220","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.00866-09","article-title":"Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization","volume":"84","author":"Cheng","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0225","doi-asserted-by":"crossref","first-page":"e33969","DOI":"10.1371\/journal.pone.0033969","article-title":"Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0230","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0235","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0240","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4049\/jimmunol.170.3.1416","article-title":"A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag","volume":"170","author":"Fitzgerald","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0245","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.virol.2004.03.047","article-title":"Complete nucleotide sequences and genome organization of four chimpanzee adenoviruses","volume":"324","author":"Roy","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0250","doi-asserted-by":"crossref","first-page":"10774","DOI":"10.1128\/JVI.00810-11","article-title":"Novel adenoviruses in wild primates: a high level of genetic diversity and evidence of zoonotic transmissions","volume":"85","author":"Wevers","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0255","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0260","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0265","doi-asserted-by":"crossref","first-page":"e20977","DOI":"10.1371\/journal.pone.0020977","article-title":"Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1","volume":"6","author":"Biswas","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0270","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0275","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys","volume":"482","author":"Barouch","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0280","doi-asserted-by":"crossref","first-page":"7760","DOI":"10.1128\/JVI.00599-12","article-title":"Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates","volume":"86","author":"Flatz","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0285","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1128\/JVI.76.11.5357-5368.2002","article-title":"Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization","volume":"76","author":"Chakrabarti","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0290","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/jvi.70.9.6497-6501.1996","article-title":"A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4","volume":"70","author":"Brough","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0295","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1128\/IAI.00315-10","article-title":"New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1","volume":"78","author":"Goodman","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0300","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1006\/viro.1993.1442","article-title":"Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein","volume":"195","author":"Cox","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0305","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1128\/JVI.01811-08","article-title":"Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors","volume":"83","author":"Ko","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0310","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1128\/JVI.02108-09","article-title":"Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies","volume":"84","author":"Seaman","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0315","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1128\/JVI.02616-07","article-title":"Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys","volume":"82","author":"Liu","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0320","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1371\/journal.ppat.0030025","article-title":"Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells","volume":"3","author":"Cheng","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0325","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.4049\/jimmunol.1000338","article-title":"CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling","volume":"185","author":"Lindsay","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0330","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1517\/14712590903307388","article-title":"Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors","volume":"9","author":"Seregin","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0335","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcb.22328","article-title":"The influence of innate and pre-existing immunity on adenovirus therapy","volume":"108","author":"Zaiss","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0340","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.gt.3300978","article-title":"Poly-l-lysine improves gene transfer with adenovirus formulated in PLGA microspheres","volume":"6","author":"Matthews","year":"1999","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0345","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/10430349950018021","article-title":"PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo","volume":"10","author":"O\u2019Riordan","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0350","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0355","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1128\/JVI.73.7.6056-6065.1999","article-title":"Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors","volume":"73","author":"Miyazawa","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0360","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0365","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/14712590903187053","article-title":"Engineered adenovirus serotypes for overcoming anti-vector immunity","volume":"9","author":"Dharmapuri","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0370","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0375","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.vaccine.2011.12.026","article-title":"SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses","volume":"30","author":"Lai","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0380","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0385","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0390","doi-asserted-by":"crossref","first-page":"e9015","DOI":"10.1371\/journal.pone.0009015","article-title":"Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses","volume":"5","author":"Koup","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0395","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/aid.1991.7.831","article-title":"High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas","volume":"7","author":"Carrow","year":"1991","journal-title":"AIDS Res Hum Retrovirus"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0400","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.4049\/jimmunol.153.4.1895","article-title":"The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides","volume":"153","author":"Vogel","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0405","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.virol.2007.09.024","article-title":"Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope","volume":"372","author":"Zolla-Pazner","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.10.023_bib0410","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/JVI.02252-09","article-title":"Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs","volume":"84","author":"Nkolola","year":"2010","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15014383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15014383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:22:01Z","timestamp":1759400521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15014383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":41,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0264410X15014383"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}